Skip to main content

Breadcrumb

  1. Home
  2. DUET-CD: A study of an investigational study…
  • General Information >>
  • Eligibility >>
  • Study Details >>
  • Contact Information >>

DUET-CD: A study of an investigational study medication in participants with Moderately to Severely Active Crohn's Disease

Published: 09/01/2023

General Information:

Click Here to Learn More »
Study Objective

The purpose of the DUET study is to evaluate the efficacy and safety of the investigational combination therapy of two investigational medications in participants with moderately to severely active Crohn's disease.

Phase of study
Phase 2
RETURN TO TOP

Eligibility:

Age
Adult (18+)
Gender
Female
Male
Disease Type
Crohn's Disease
Severity
Moderate
Severe
Eligibility Criteria

You may be able to take part in the DUET study if you meet the following criteria:

  • Age range is 18-65 years, inclusive.
  • Have been diagnosed with CD for at least three months.
  • Have moderately to severely active CD.
  • Have previously demonstrated lack of initial response, responded initially but then lost response with continued therapy, or was intolerant to 1 or more Advanced drug therapies (ADTs) at a dose approved for the treatment of CD.

 

RETURN TO TOP

Study Details:

Study description/explanation of participation:

  • The study will last up to 256 weeks. During this time, you will have study visits approximately every 4 weeks.

  • The study medicine will be administered by injection given subcutaneously (under the skin)

  • You may receive a placebo (containing no active medication) or the investigational medicine. The chance of being assigned to Placebo is 9%

  • If you initially receive a placebo in the primary stage of the study and you do not respond you will be switched to the active medication after 24-weeks. You will already have started the maintenance phase at this stage.

  • Study participants will receive study-required medical care at no cost

Description of treatment or intervention (mechanism of action):

The investigational combined study medication is being tested to see if it will reduce inflammation in the intestines. It will be administered by injection given subcutaneously (under the skin). The co-formulation of the medicine was first studied in a Phase 2a study for Ulcerative Colitis and is being tested for Crohn’s disease for the first time. It is not yet approved for CD in any country. Therefore, it can only be used in a research study such as this one.

Participation requirements:

  • Come to all study visit appointments

  • Complete a diary and bring it with you to appointments

  • Tell the study doctor/staff about any health problems you have during the study

Possible risks and side effects:

Because we are learning about the study medications in combination, all possible side effects and risks related to the study medicine are not known and there is the potential that you may experience side effects. All potential side effects will be discussed by the study staff before you begin the study.

Side effects may range from mild and unpleasant to serious, or even life-threatening. If you do experience side effects and/or discomfort during the study, you can contact the study doctor at any time to discuss the best course of action. Throughout the study, your health will be continuously monitored.

RETURN TO TOP

Contact Information:

Site Locations

University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic 1010 N Kansas St. Wichita, Kansas 67214
Hannah Hancock
(316) 293-1833
[email protected]
BVL Clinical Research 840 W Kansas Street Suite A Liberty, Missouri 64068
Mike Niemeyer
(785) 217-6559
[email protected]
Rutgers University Hospital - Gastroenterology 125 Paterson Street Research Pharmacy CRC East Tower 8th Floor New Brunswick, New Jersey 08091
Sheila Redding
1 (732) 235-6121
[email protected]
Amel Med LLC. Research 12701 Ranch Road North Austin, Texas 78750
Meghan Smith M.D.
(512) 593-6022
[email protected]
Cotton O'Neil Clinical Research Center 720 Sw Lane St. Topeka, Kansas 66606
Andrea Clark
(785)-270-4856
[email protected]
Baylor Scott & White Center for Inflammatory Bowel Diseases 621 Hall St. Dallas, Texas 75226
Mariana Hurutado
1 (214) 820-7755
[email protected]
Gastroenterology Associates of the Piedmont, P.A. 215 Executive Park Blvd Suite 106 Winston-Salem, North Carolina 27103
Regina Tilley
336-779-1266
[email protected]
Galen Digestive Health 4976 Alpha Lane Hixson, Tennessee 37343
Tracey Herman
423-308-0280 ext 1076
[email protected]
Click Here to Learn More »
RETURN TO TOP

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari